Role of diuretics in the prevention of heart failure: The antihypertensive and lipid-lowering treatment to prevent heart attack trial

Barry R. Davis, Linda B. Piller, Jeffrey A. Cutler, Curt Furberg, Kay Dunn, Stanley Franklin, David Goff, Frans Leenen, Syed M. Mohiuddin, Vasilios Papademetriou, Michael Proschan, Allan Ellsworth, John Golden, Pedro Colon, Richard Crow

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background - Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) stipulated assessment of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing HF. Methods and Results - ALLHAT was a double-blind, randomized, clinical trial in 33 357 high-risk hypertensive patients aged ≥55 years. Hospitalized/fatal HF outcomes were examined with proportional-hazards models. Relative risks (95% confidence intervals; P values) of amlodipine or lisinopril versus chlorthalidone were 1.35 (1.21 to 1.50;

Original languageEnglish
Pages (from-to)2201-2210
Number of pages10
JournalCirculation
Volume113
Issue number18
DOIs
StatePublished - May 2006

Fingerprint

Diuretics
Chlorthalidone
Antihypertensive Agents
Lisinopril
Amlodipine
Heart Failure
Myocardial Infarction
Lipids
Proportional Hazards Models
Therapeutics
Randomized Controlled Trials
Confidence Intervals
Hypertension

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Role of diuretics in the prevention of heart failure : The antihypertensive and lipid-lowering treatment to prevent heart attack trial. / Davis, Barry R.; Piller, Linda B.; Cutler, Jeffrey A.; Furberg, Curt; Dunn, Kay; Franklin, Stanley; Goff, David; Leenen, Frans; Mohiuddin, Syed M.; Papademetriou, Vasilios; Proschan, Michael; Ellsworth, Allan; Golden, John; Colon, Pedro; Crow, Richard.

In: Circulation, Vol. 113, No. 18, 05.2006, p. 2201-2210.

Research output: Contribution to journalArticle

Davis, BR, Piller, LB, Cutler, JA, Furberg, C, Dunn, K, Franklin, S, Goff, D, Leenen, F, Mohiuddin, SM, Papademetriou, V, Proschan, M, Ellsworth, A, Golden, J, Colon, P & Crow, R 2006, 'Role of diuretics in the prevention of heart failure: The antihypertensive and lipid-lowering treatment to prevent heart attack trial', Circulation, vol. 113, no. 18, pp. 2201-2210. https://doi.org/10.1161/CIRCULATIONAHA.105.544031
Davis, Barry R. ; Piller, Linda B. ; Cutler, Jeffrey A. ; Furberg, Curt ; Dunn, Kay ; Franklin, Stanley ; Goff, David ; Leenen, Frans ; Mohiuddin, Syed M. ; Papademetriou, Vasilios ; Proschan, Michael ; Ellsworth, Allan ; Golden, John ; Colon, Pedro ; Crow, Richard. / Role of diuretics in the prevention of heart failure : The antihypertensive and lipid-lowering treatment to prevent heart attack trial. In: Circulation. 2006 ; Vol. 113, No. 18. pp. 2201-2210.
@article{673b454c4a594840abf5cc206f61206e,
title = "Role of diuretics in the prevention of heart failure: The antihypertensive and lipid-lowering treatment to prevent heart attack trial",
abstract = "Background - Hypertension is a major cause of heart failure (HF) and is antecedent in 91{\%} of cases. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) stipulated assessment of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing HF. Methods and Results - ALLHAT was a double-blind, randomized, clinical trial in 33 357 high-risk hypertensive patients aged ≥55 years. Hospitalized/fatal HF outcomes were examined with proportional-hazards models. Relative risks (95{\%} confidence intervals; P values) of amlodipine or lisinopril versus chlorthalidone were 1.35 (1.21 to 1.50;",
author = "Davis, {Barry R.} and Piller, {Linda B.} and Cutler, {Jeffrey A.} and Curt Furberg and Kay Dunn and Stanley Franklin and David Goff and Frans Leenen and Mohiuddin, {Syed M.} and Vasilios Papademetriou and Michael Proschan and Allan Ellsworth and John Golden and Pedro Colon and Richard Crow",
year = "2006",
month = "5",
doi = "10.1161/CIRCULATIONAHA.105.544031",
language = "English",
volume = "113",
pages = "2201--2210",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Role of diuretics in the prevention of heart failure

T2 - The antihypertensive and lipid-lowering treatment to prevent heart attack trial

AU - Davis, Barry R.

AU - Piller, Linda B.

AU - Cutler, Jeffrey A.

AU - Furberg, Curt

AU - Dunn, Kay

AU - Franklin, Stanley

AU - Goff, David

AU - Leenen, Frans

AU - Mohiuddin, Syed M.

AU - Papademetriou, Vasilios

AU - Proschan, Michael

AU - Ellsworth, Allan

AU - Golden, John

AU - Colon, Pedro

AU - Crow, Richard

PY - 2006/5

Y1 - 2006/5

N2 - Background - Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) stipulated assessment of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing HF. Methods and Results - ALLHAT was a double-blind, randomized, clinical trial in 33 357 high-risk hypertensive patients aged ≥55 years. Hospitalized/fatal HF outcomes were examined with proportional-hazards models. Relative risks (95% confidence intervals; P values) of amlodipine or lisinopril versus chlorthalidone were 1.35 (1.21 to 1.50;

AB - Background - Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) stipulated assessment of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing HF. Methods and Results - ALLHAT was a double-blind, randomized, clinical trial in 33 357 high-risk hypertensive patients aged ≥55 years. Hospitalized/fatal HF outcomes were examined with proportional-hazards models. Relative risks (95% confidence intervals; P values) of amlodipine or lisinopril versus chlorthalidone were 1.35 (1.21 to 1.50;

UR - http://www.scopus.com/inward/record.url?scp=33646766401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646766401&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.105.544031

DO - 10.1161/CIRCULATIONAHA.105.544031

M3 - Article

C2 - 16651474

AN - SCOPUS:33646766401

VL - 113

SP - 2201

EP - 2210

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 18

ER -